Liquidity under financial statement analysis refers to an asset’s ability to be converted into cash without necessarily affecting its market value. When undertaking an investment decision in a company, various parameters prove useful in understanding its viability. In the case of CVS Health Corporation, the previous part’s extensive review sheds light on the institution’s functionality. The first liquidity parameter previewed entails the current ratio. The mentioned metric shows the current assets’ ability to satisfy maturing short-term obligations as and when they fall due. From the evaluation, the generated figure is 0.94. there required standard value is usually 2.00 for any given business venture. CVS’s performance alludes to the fact that the institution is incapable of fulfilling the maturing short term responsibilities as and when they fall due. The inventory turnover metric ascertains the number of times stock was turned into sales within a period of one year. The value of 29 connotes slow realization of revenue from the sale of inventory. The observation equally translates to slow cash flow cycles in the company. The debt-to-asset ratio communicates the amount of debt utilized in the acquisition of the assets of the institution. The value of 0.71 or 71% implies that a substantial portion of asset financing is from the borrowed resources for every. The debt-to-equity ratio equally demonstrates the amount of debt in the capital structure of CVS Health Corporation. The calculations from the latest financial year reveal a figure of 2.47. the profit margin ratio examines the profitability of the business. The parameter ascertains how well an institution can manage and account for its expenses. The rationale mentioned communicates to the investors whether enough income will remain to be shared as dividends. For the creditors, the same metric demonstrates whether resources are enough to pay the corporation’s debts. From the highlighted observations about the company’s performance, its evident a clear investment decision is realizable, even without exploring other additional criteria. When the debt-to-equity ratio of a company stands at 0.71 or 71%, it shows a substantial reliance on creditors for the organization’s operations. The highlighted situation translates to a dilution of shareholders’ control of the venture. When the shareholders can no longer make critical decisions without the interference of the creditor creditors. An individual cannot invest in such an entity. Having a current ratio of 0.94 shows that management can’t even accommodate outsiders’ short term obligation. The numerous highlighter yardsticks show that CVS Health Corporation isn’t a venture worth investing in. From the analysis of the period 2018 and 2019, there was a minimal increase in shareholding within the corporation. The mentioned development illustrates a minimal appetite from the market investor to buy the company shares. The mentioned scenario further vindicates how precarious its for one to attempt investing in CVS Health Corporation. Equally, over the years, diversified by investing in subsidiary ventures. The expansive list of institutions under the firm’s umbrella alludes to the near realization of marbusiness’s ket saturation. Therefore the growth pattern and potential of the firm are minimal. The scenario case means the entity has little room to expand and increase revenues; hence, profits for its stakeholders-concern concept are extremely fundamental for any given investment. When an investor is unconvinced about the firm’s ability to continue in operation beyond the management’s lives, a difficult case emerges in support of buying interest into such an institution. The market share price offers the first narrative about the performance and viability of the company. In the case of CVS Health, shares’ current market price is lower than in the previous trading periods. By studying the share price movement, one can tell stability isn’t assured on the future growth in the institution’s value. Therefore, the firm’s inherent value is jeopardized, making it difficult to present a substantive case to the market investors. The company’s outlined variable all seems to converge at a singular conclusion – the corporation isn’t an attraction for any potential investor. The undesirable performances in profitability, liquidity, solvency, and growth and expansion don’t make a positive case. Investors must have the assurance that their returns both in the short and long term are assured. Equally, they must be confident in the growth and expansion of the venture, which henceforth supports the investor’s portfolio diversification agenda. Equally, control in the stake of the firm is equally critical. Nobody wants to buy an interest in a company today, only to realize down the line the creditors are the ones calling the shots in key management decisions. In conclusion, I won’t invest in CVS Health Corporation, nor could I support or encourage somebody to do the same – the institution is simply a decision away from a crisis. 58.43, 58.08, 56.87, and 57.84 are the trading prices for the mentioned dates, respectively. The dividend declaration of 0.5 further vindicates the communicated position above about its status as an investment opportunity.
Also, please include the trading price on the following dates:
October 1, October 15, November 1, and November 15.